Bivalirudin
FDA-approved IV (into a vein) DTI for PCI (a heart artery procedure).
What it's for
FDA-approved IV (into a vein) DTI for PCI (a heart artery procedure).
What it's for
Bivalirudin is a 20–amino-acid lab-made peptide modeled on hirudin that directly inhibits thrombin. Used as an anticoagulant in percutaneous coronary intervention and related labeled settings.
What it does for the body
Used as an anticoagulant in percutaneous coronary intervention and related labeled settings. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Reversible binding to thrombin’s active site and exosite I inhibits fibrin formation. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Bivalirudin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Heart research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Bivalirudin — FDA.gov search
- ClinicalTrials.gov search: Bivalirudin — U.S. clinical trials registry
- Drugs@FDA search: Bivalirudin — FDA drug database (if approved)
- PubMed search: Bivalirudin — NCBI PubMed
- PubMed Central search: Bivalirudin — NCBI PMC